ProMetic Reports Director Election Results at AGM

ProMetic Reports Director Election Results at AGM 
LAVAL, QUEBEC -- (Marketwired) -- 05/09/13 -- ProMetic Life Sciences
Inc. (TSX:PLI)(OTCQX:PFSCF) ("ProMetic"or the "Corporation") today
reported pursuant to new regulatory disclosure obligations that all
nominees listed in the management proxy circular dated March 22, 2013
were elected as directors of ProMetic at its annual and special
meeting of shareholders (AGM) held on May 8, 2013 in Montreal
According to the proxies, a total of 145,176,247 Common shares were
voted at the meeting, representing 29.80% of the votes attached to
all outstanding shares. Shareholders voted in favor of all items of
business, including the election of all director nominees as follows: 

                                              %          votes       % votes
Nominee                  votes For    votes For       Withheld      Withheld
G.F. Kym Anthony       132,811,405        99.15      1,132,610          0.85
Michael J. Brunelle    132,762,350        99.12      1,181,665          0.88
Raymond M. Hakim       132,790,750        99.14      1,153,265          0.86
Robert Lacroix         131,931,255        98.50      2,012,760          1.50
Pierre Laurin          132,968,910        99.27        975,105          0.73
Louise Menard          132,289,305        98.76      1,654,710          1.24
Paul Mesburis          132,961,905        99.27        982,110          0.73
John Moran             132,789,505        99.14      1,154,510          0.86
Nancy Orr              131,9
82,200        98.54      1,961,815          1.46
Bruce Wendel           130,124,550        97.15      3,819,465          2.85
Benjamin Wygodny       132,772,450        99.13      1,171,565          0.87

The directors were elected to hold offices until the next annual
meeting of shareholders or until their successors are elected or
appointed. Detailed voting results for the meeting are available on
SEDAR at  
New Directors Elected  
Dr. Hakim served as Chief Medical Officer and Senior Executive Vice
President, Clinical & Scientific Affairs for Fresenius Medical
Services North America. Dr. Hakim completed his Nephrology fellowship
at Harvard Medical School and at Brigham and Women's Hospital in
Boston. He went on to serve as Medical Director of Dialysis Clinical
Services at Vanderbilt University Hospital. In 1995, Dr. Hakim became
one of the founders of Renal Care Group which later merged with
Fresenius Medical Care North America.  
Dr Hakim is joining existing Director, Dr. John Moran to support the
advancement of ProMetic's lead drug candidates for the treatment of
Chronic Kidney Diseases.  
Michael J. Brunelle currently serves as Vice President of Development
for NantWorks and Affiliated Organizations. Mr. Brunelle serves on
the board of directors for Strand Diagnostics, Expression Pathology
and Dithera. Mr. Brunelle has over 30 years of health care experience
as a consultant, investment banker and entrepreneur.  
About ProMetic Life Sciences Inc.  
ProMetic Life Sciences Inc. ("ProMetic") ( is a
biopharmaceutical company specialized in the research, development,
manufacture and marketing of a variety of commercial applications
derived from its proprietary Mimetic Ligand(TM) technology. This
technology is used in large-scale purification of biologics and the
elimination of pathogens. ProMetic is also active in therapeutic drug
development with the mission to bring to market effective,
innovative, lower cost, less toxic products for the treatment of
hematology and cancer. Its drug discovery platform is focused on
replacing complex, expensive proteins with synthetic "drug-like"
protein mimetics. Headquartered in Laval (Canada), ProMetic has R&D
facilities in the U.K., the U.S. and Canada, manufacturing facilities
in the U.K. and business development activities in the US, Europe,
Forward Looking Statements  
This press release contains forward-looking statements about
ProMetic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward -looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events or
results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, ProMetic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful and
timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and general
changes in economic conditions. You will find a more detailed
assessment of the risks that could cause actual events or results to
materially differ from our current expectations in ProMetic's Annual
Information Form for the year ended December 31, 2012, under the
heading "Risk and Uncertainties related to ProMetic's business". As a
result, we cannot guarantee that any forward-looking statement will
materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of
future events or for any other reason, unless required by applicable
securities laws and regulations. All amounts are in Canadian dollars
unless indicated otherwise.
Pierre Laurin
President and CEO
ProMetic Life Sciences Inc.
Frederic Dumais
Director, Communications and
Investor Relations
ProMetic Life Sciences Inc.
Press spacebar to pause and continue. Press esc to stop.